| |
Washington
State
Medical
Oncology
Society |
| |
| | |
Jeffery C. Ward, M.D.
Puget Sound Cancer Centers
Edmonds |
|
Richard A. McGee, M.D., F.A.C.P.
Puget Sound Cancer Centers
Renton
|
|
Thomas E. Boyd, M.D.
North Star Lodge
Yakima
James Congdon, D.O.
Providence Regional Cancer Partnership
Everett
Vicky E. Jones, M.D.
North Star Lodge
Yakima
Kenneth G. Kraemer, M.D.
Eastside Oncology Hematology
Bellevue
Ann E. Murphy
Harrison HealthPartners
Bremerton
John A. Thompson, M.D.
Seattle Cancer Care Alliance
Seattle
Howard (Jack) West
Swedish Cancer Institute
Seattle
Robert Witham, M.D.
Office of Robert R. Witham, MD, Inc., P.S.
Port Angeles |
| |
Vincent J. Picozzi, Jr., M.D., MMM
Virginia Mason Medical Center
Seattle
|
|
Jonathan C. Britell, M.D.
Southlake Clinic
Renton
|
|
Jeffery C.Ward, M.D.
Puget Sound Cancer Centers
Edmonds
Richard A. McGee, M.D., F.A.C.P.
Puget Sound Cancer Centers
Edmonds
|
|
Jeffery C. Ward, M.D.
Puget Sound Cancer Centers
Edmonds
Richard A. McGee, M.D., F.A.C.P.
Puget Sound Cancer Centers
Edmonds
|
|
Risë Marie Cleland
Vancouver
|
| | |
|
|
Sanofi-aventis Announces Jevtana Approval
Sanofi-aventis is pleased to announce that on June 17, 2010, the US Food and Drug Administration (FDA) approved Jevtana® (cabazitaxel) Injection.
In addition, as of July 19, 2010, Jevtana is now commercially available.
Product related billing information is provided below:
- National Drug Codes (NDCs)
- NDC Assigned: 00024-5824-11
- Packaging: Carton of one (1) Jevtana vial & one (1) Diluent vial
- HCPCS Codes
- J9999 Not otherwise classified (NOC) antineoplastic drugs
- C9399 Unclassified drugs or biologicals
For more information on Jevtana, please click here for full prescribing information, including boxed WARNING.
Updated VELCADE Label Announced
On January 4, 2010 Millennium announced that the FDA has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term overall survival data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. the VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). Click Here to read the press release, Click Here to read the Physician Announcement Letter
|
|
|
This website brought to you by:
Washington State Medical Oncology Society
113 W. 7th Street Suite 205
Vancouver, Washington 98660
360.258.0443 Phone 360.695.6937 Fax
wsmos@comcast.net |
| |
| | | |